Prostate Cancer Imaging Just Got a Boost
Axumin approved to detect recurrent prostate cancer
The US Food and Drug Administration (FDA) recently approved a new diagnostic imaging tool to detect prostate cancer that has come back after treatment.
Axumin, an injected, radioactive diagnostic agent, was approved in men with suspected recurrent prostate cancer based on elevated prostate-specific antigen (PSA) levels.
Prostate cancer remains a leading cause of death in men in the US, according to the FDA.
Axumin, approved for positron emission tomography (PET) imaging, is meant to help doctors detect recurrent prostate cancer. It does not treat the cancer.
A radioactive substance, Axumin should be handled with care, according to the FDA.
Two studies found that Axumin appeared safe and effective. Common adverse events reported with Axumin use included redness or pain at the injection site and a metallic taste in the mouth.
Blue Earth Diagnostics markets Axumin.
All information on this site is provided “as-is” for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health.
More health news
Prescription DrugsImaging Cancer’s Return
Prostate cancer imaging agent that spots recurrence wins FDA approval
Health NewsImaging Agent Helps “See” Prostate Cancer
Prostate cancer imaging substance approved by FDA
Health NewsFDA Approves Prostate Cancer Imaging Agent
Choline C 11 Injection is a PET imaging agent